Article Details
Retrieved on: 2023-10-23 19:22:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Roche has agreed to acquire Telavant Holdings, maker of an inflammatory bowel disease drug, from Roivant Sciences and Pfizer for $7.25 billion.
Article found on: www.beckershospitalreview.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here